<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41127">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570984</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00019640</org_study_id>
    <nct_id>NCT02570984</nct_id>
  </id_info>
  <brief_title>Controlling and Preventing Asthma Progression and Severity in Kids</brief_title>
  <acronym>CASK</acronym>
  <official_title>Controlling and Preventing Asthma Progression and Severity in Kids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wanda Phipatanakul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a randomized, double-blind, placebo controlled trial designed to test whether
      two years treatment of preschool children aged 2-3 years of age at high risk for asthma with
      omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as
      reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2
      year observation period off study drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prevention/ Disease modification of asthma.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>active asthma diagnosis</measure>
    <time_frame>Final 12 months during 2 year observation period off study drug</time_frame>
    <description>questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number asthma exacerbations</measure>
    <time_frame>Final 12 months during 2 year observation period off study drug</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>forced expiratory flow volume in 1 second (FEV1)</measure>
    <time_frame>during 2 year observation period</time_frame>
    <description>lung function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptom free days</measure>
    <time_frame>every month during 2 year observation period</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of positive allergic sensitization</measure>
    <time_frame>final year during 2 year observation period</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of asthma exacerbations</measure>
    <time_frame>during 2 year treatment</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>omalizumab 0.016 mg/kg/IU/cc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>looks like active drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>anti-ige injection</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo comparator arm, injection similar to active</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  24-47 months at randomization

          -  positive allergy to aeroallergen

          -  1-2 wheezing episodes past year

        Exclusion Criteria:

          -  other chronic lung disease besides asthma

          -  allergy to study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>47 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wanda Phipatanakul, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wanda Phipatanakul, MD, MS</last_name>
    <phone>857-218-5336</phone>
    <email>wanda.phipatanakul@childrens.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doris Schierembergg, MD, MPH</last_name>
    <phone>857-218-5336</phone>
    <email>asthma@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando Martinez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Fitzpatrick, PhD, NP</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wanda Phipatanakul, MD, MS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonard Bacharier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 8, 2016</lastchanged_date>
  <firstreceived_date>July 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital, Boston</investigator_affiliation>
    <investigator_full_name>Wanda Phipatanakul</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
